Novartis says Cosentyx delivers long-term psoriasis results; Merck's Keytruda nabs two NICE nods;

> Novartis ($NVS) unveiled new data showing that a majority of psoriasis patients using Cosentyx were able to maintain clear or almost clear skin for three years. Release

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won two green lights from cost-effectiveness watchdogs in England last week, one in previously treated advanced melanoma and the other in patients newly diagnosed with the disease. Report

> Eli Lilly & Co. ($LLY) bought the rights to a potential treatment for severe hypoglycemia, delivered as a nasal spray, saying it could be the "first needle-free rescue" product for diabetics. Report

> Basilea Pharmaceutica said Health Canada approved its drug Zevtera as a treatment for bacterial lung infections. Report

> Eli Lilly & Co. expanded a cancer-drug partnership in China with Innovent Biologics to cover three potential products and up to $1 billion in milestone payments over the next decade. Report

> Quest Diagnostics ($DGX) said its PD-L1 diagnostic test was approved by the FDA in tandem with Bristol-Myers Squibb's ($BMY) Friday green light for Opdivo in nonsquamous non-small cell lung cancer. Release

> Amgen's ($AMGN) Prolia delivered larger gains in bone-mineral density than the IV bisphosphonate drug zoledronic acid in postmenopausal women with osteoporosis who'd previously been treated with bisphosphonates. Release

And Finally... Potential new pain drugs are struggling to deliver placebo-beating clinical trial data because of an increasingly strong placebo effect in pain studies. Report

Suggested Articles

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.